university | Science and Enterprise

A new company developing treatments to relieve allergic reactions with reprogrammed antibodies began work and is ra… https://t.co/LFNVxych8d
about 4 hours ago
New post on Science and Enterprise: New Allergy Biotech Launches, Raises $10M https://t.co/x5W0TwnCBu #Science #Business
about 4 hours ago
Two companies and NIH are beginning a clinical trial of synthetic antibodies to both treat and prevent Covid-19 inf… https://t.co/LaUrUiRmhk
about 23 hours ago
New post on Science and Enterprise: Trial Set for Covid-19 Antibodies in Long-Term Care https://t.co/tF0a7CDgGr #Science #Business
about 23 hours ago
The numbers of vaccine candidates in development and clinical trials show modest but steady growth, now up to 157 a… https://t.co/AO2DxxTgF8
about 1 day ago

New Allergy Biotech Launches, Raises $10M

By Alan, on August 4th, 2020%

A new company developing treatments to relieve allergic reactions with reprogrammed antibodies began work and is raising $10 million in its first venture funding round. . . . → Read More: New Allergy Biotech Launches, Raises $10M

A.I. Employed for Local Covid-19 Prediction Models

By Alan, on July 31st, 2020%

Computer scientists in California are writing deep learning algorithms that generate forecasts for Covid-19 infections in local communities. . . . → Read More: A.I. Employed for Local Covid-19 Prediction Models

Sensor Patch Captures Health Indicators in Sweat

By Alan, on July 29th, 2020%

A bio-engineering lab created a wearable fabric patch with threads configured into sensors that capture and measure health indicators from human sweat. . . . → Read More: Sensor Patch Captures Health Indicators in Sweat

Neuro Disease Start-Up Raises $73M in Early Funds

By Alan, on July 29th, 2020%

A company developing new therapies for neurodegenerative diseases officially began operations, staked to $73 million raised in its first venture round. . . . → Read More: Neuro Disease Start-Up Raises $73M in Early Funds

Trial Testing Lymphoma Drug to Treat Covid-19

By Alan, on July 28th, 2020%

A clinical trial is underway testing an experimental drug for lymphoma and neurological disorders also as a treatment for early Covid-19 infections. . . . → Read More: Trial Testing Lymphoma Drug to Treat Covid-19

Synthetic Protein Designed to Boost Covid-19 Vaccines

By Alan, on July 24th, 2020%

Researchers in Texas designed a synthetic version of a protein found on Covid-19 viruses that can make it easier to produce more vaccines. . . . → Read More: Synthetic Protein Designed to Boost Covid-19 Vaccines

Trial Testing Point-of-Care Covid-19 Diagnostic

By Alan, on July 23rd, 2020%

A clinical trial in the U.K. is assessing a testing device to detect Covid-19 viruses in nasal swab samples that returns results in an hour. . . . → Read More: Trial Testing Point-of-Care Covid-19 Diagnostic

Start-Up Developing Inside-Cell Delivery, Gains $28.5M

By Alan, on July 22nd, 2020%

A new company spun-off from Harvard University is developing techniques for delivering advanced genetic and protein therapies directly inside cells. . . . → Read More: Start-Up Developing Inside-Cell Delivery, Gains $28.5M

Tough Surgical Adhesive Commercially Licensed

By Alan, on July 21st, 2020%

A bio-materials company is acquiring the rights to develop dental sutures and membranes from an adhesive gel developed in a university lab. . . . → Read More: Tough Surgical Adhesive Commercially Licensed

Gene Therapy Production Company Opens, Raises $40M

By Alan, on July 21st, 2020%

A new enterprise developing and manufacturing gene therapies, both its own and for others, is underway, raising $40 million in venture funds. . . . → Read More: Gene Therapy Production Company Opens, Raises $40M

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise